Massive 50,000-Patient study tracks new kidney drug in real life

NCT ID NCT06278207

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study is collecting information about how the drug finerenone is used in everyday medical practice for people with chronic kidney disease and type 2 diabetes. Researchers will analyze existing health records from 50,000 patients in Asia and the United States who are already taking finerenone as prescribed by their doctors. The goal is to understand who receives this medication, how they take it, and what health outcomes they experience in real-world settings.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bayer

    RECRUITING

    Berlin, 13353, Germany

  • Many Locations

    COMPLETED

    Multiple Locations, New Jersey, 07981, United States

  • Many Locations

    COMPLETED

    Multiple Locations, Japan

  • Many Locations

    COMPLETED

    Multiple Locations, Taiwan

Conditions

Explore the condition pages connected to this study.